-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下: COHR公布2026财年第三季度营收为18.1亿美元(同比增长21%),高于市场普遍预期的17.8亿美元;非GAAP每股收益为1.41美元(同比增长55%),也高于华尔街预期的1.39美元。数据中心和通信业务营收同比增长41%,占总销售额的75%;受宏观经济不利因素影响,工业业务营收按备考基准下降2%。我们认为,利润率的显著提升证明了公司强劲的运营能力,非GAAP毛利率达到39.6%(同比增长105个基点),营业利润率达到20.3%(同比增长163个基点)。第四季度业绩指引超出预期,营收中值为19.8亿美元(同比增长29%),非GAAP每股收益为1.62美元(同比增长62%),而市场普遍预期分别为19.1亿美元和1.54美元。我们认为,随着获得一笔数额巨大的采购订单以及英伟达的股权投资,CPO业务的增长势头持续增强,这进一步印证了其前景。我们预计,到2027年,InP产能翻番的计划将释放更多增长潜力,因为高利润率的1.6T收发器和6英寸晶圆将推动产品组合的优化。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.